The patent, titled "Computer Systems and Methods for Genomic Analysis," builds on a previous patent granted to the company in 2020. The methods form the basis of genome-wide association studies, especially those focused on identifying single-nucleotide polymorphisms associated with drug response (i.e., pharmacogenomic or pharmacogenetic markers), according to Genetic Technologies.

The patent represents the foundation of a single test encompassing multiple serious diseases, the company said. The test is scheduled for release in the fourth quarter of 2021.